|  |  |
| --- | --- |
|   | **Mean ± SD**  |
| **Variable (n)** |  |  | **Treatment effect****(comparison** **pre/post)** |
| **Pre-****treatment** | **Post-****treatment** | **F(d.f.); *p*-value****(eta2)** |
| **RNFL average thickness (µm)** |  |  | F(1.38)=1.254; p=0.270 |
|  **CPAP (10)** | 95.5 ± 11.1 | 94.8 ± 9.3 | (0.032) |
|  **Surgery (19)** | 105.7 ± 8.4 | 104.9 ± 7.2 |  |
|  **CPAP + surgery (12)** | 102.4 ± 4.6 | 100.3 ± 5.9 |  |
| **Total** | 102.2 ± 9.1 | 101.1 ± 8.3 |   |
| **RNFL superior quadrant thickness (µm)** |  |  | F(1.38)=0.112; p=0.740 |
|  **CPAP (10)** | 119.7 ± 11.7 | 116.8 ± 14.3 | (0.003) |
|  **Surgery (19)** | 131.7 ± 12.5 | 130.5 ± 15.0 |  |
|  **CPAP + surgery (12)** | 135.3 ± 10 | 132.8 ± 8.9 |  |
| **Total** | 129.1 ± 12.6 | 128.6 ± 14.8 |   |
| **RNFL nasal quadrant thickness (µm)** |  |  | F(1.38)=1.692; p=0.201 |
|  **CPAP (10)** | 71.5 ± 19.9 | 72.2 ± 18.3 | (0.043) |
|  **Surgery (19)** | 80.7 ± 14.9 | 79.5 ± 11.6 |  |
|  **CPAP + surgery (12)** | 71.2 ± 13.9 | 65.2 ± 9.5 |  |
| **Total** | 75.7 ± 16.3 | 73.5 ± 14.1 |   |
| **RNFL inferior quadrant thickness (µm)** |  |  | F(1.38)=0.460; p=0.502 |
|  **CPAP (10)** | 117.3 ± 20.7 | 117.4 ± 19.9 | (0.012) |
|  **Surgery (19)** | 136.8 ± 13.6 | 135.7 ± 14.8 |  |
|  **CPAP + surgery (12)** | 124.9 ± 12.1 | 121.1 ± 11.9 |  |
| **Total** | 128.6 ± 17 | 127 ± 17.2 |   |
| **RNFL temporal quadrant thickness (µm)** |  |  | F(1.38)=0.039; p=0.845 |
|  **CPAP (10)** | 73.6 ± 7.8 | 74.7 ± 10.1 | (0.001) |
|  **Surgery (19)** | 73.6 ± 10.3 | 72.6 ± 9.7 |  |
|  **CPAP + surgery (12)** | 80.6 ± 14.3 | 79.7 ± 15.3 |  |
| **Total** | 75.6 ± 11.3 | 75.2 ± 11.8 |   |

Table extra 1. Evolution of peripapillary RNFL thicknesses in the mild-moderate OSA group (43 eyes evaluated from 23 patients). GLM: General Linear Model; SD: standard deviation; df: degrees of freedom; eta2: partial eta2 (effect size); p: level of statistical significance.

|  |  |
| --- | --- |
|   | **Means ± SD** |
| **Variable (n)** |  |  | **Treatment effect** **(comparison** **pre/post)** |
| **Pre-****Treatment** | **Post-****treatment** | **F(d.f.); *p*-value** **(eta2)** |
| **RNFL average thickness (µm)** |  |  | F(1.52)=4.121; **p=0.047** |
|  **CPAP (22)** | 98.9 ± 9.1 | 100.8 ± 9.6 | (0.067) |
|  **Surgery (10)** | 97.2 ± 7.3 | 99.6 ± 5.9 |  |
|  **CPAP + surgery (23)** | 92.9 ± 11.8 | 93.8 ± 14.1 |  |
| **Total** | **96.1 ± 10.3** | **97.7 ± 11.6**  |   |
| **RNFL superior quadrant thickness (µm)** |  |  | F(1.52)=1.915; p=0.172 |
|  **CPAP (22)** | 125.1 ± 16.1 | 126 ± 13.9 | (0.036) |
|  **Surgery (10)** | 120.6 ± 20.3 | 125.3 ± 17.7 |  |
|  **CPAP + surgery (23)** | 120.4 ± 19.7 | 121.4 ± 20.1 |  |
| **Total** | 122.3 ± 18.2 | 124 ± 17.2 |   |
| **RNFL nasal quadrant thickness (µm)** |  |  | F(1.52)=1.173; p=0.284 |
|  **CPAP (22)** | 77.4 ± 17.3 | 80.8 ± 21.1 | (0.022) |
|  **Surgery (10)** | 73.9 ± 16.1 | 76.9 ± 16 |  |
|  **CPAP + surgery (23)** | 69.1 ± 11.3 | 69.6 ± 16.6 |  |
| **Total** | 73.3 ± 15 | 75.4 ± 18.8 |   |
| **RNFL inferior quadrant thickness (µm)** |  |  | F(1.52)=0.001; p=0.979 |
|  **CPAP (22)** | 120.9 ± 13.4 | 120.1 ± 29.9 | (0.000) |
|  **Surgery (10)** | 125.9 ± 13.1 | 125.6 ± 13.4 |  |
|  **CPAP + surgery (23)** | 116.6 ± 19.1 | 117.6 ± 21.5 |  |
| **Total** | 120 ± 16.1 | 120.1 ± 24 |   |
| **RNFL temporal quadrant thickness (µm)** |  |  | F(1.52)=0.706; p=0.405 |
|  **CPAP (22)** | 72.4 ± 11.6 | 71.7 ± 13 | (0.013) |
|  **Surgery (10)** | 68.2 ± 9.9 | 70.7 ± 11.5 |  |
|  **CPAP + surgery (23)** | 65.4 ± 14.9 | 67.1 ± 15.3 |  |  |
| **Total** | 68.7 ± 13 | 69.6 ± 13.7 |   |   |

Table extra 2. Evolution of peripapillary RNFL thicknesses in the severe OSA group (55 eyes evaluated from 29 patients). GLM: General Linear Model; SD: standard deviation; df: degrees of freedom; eta2: partial eta2 (effect size); p: level of statistical significance.